Bifogade filer
Q-linea’s partner Pro-Lab Diagnostics starts its first commercial evaluation in the UK
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) today announces that its appointed distributor for UK, Pro-Lab Diagnostic have started their first commercial evaluation at a large regional hospital in the Southwest of the UK. The site will assess ASTar® against other novel rapid identification and AST testing methodologies as well as the current standard of care.
“We have seen a lot of dedicated marketing and sales activities from the Pro-Lab team since the beginning of our collaboration and this evaluation is the first from a funnel of interested customers who want to understand how ASTar can improve their workflows and patient outcome,” said Thomas Fritz, Chief Commercial Officer at Q-linea.
“We are working on several projects like this in parallel at the moment which originate from conferences like ECCMID, our Seminars we are hosting several times a year and the regular interactions with customers during sales calls and are very pleased and excited about the interest we are receiving for ASTar,” said Mark Reed, General Manager at Pro-Lab Diagnostics.
About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.